261 related articles for article (PubMed ID: 29439388)
1. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
2. Flavonolignans inhibit ADP induced blood platelets activation and aggregation in whole blood.
Bijak M; Szelenberger R; Saluk J; Nowak P
Int J Biol Macromol; 2017 Feb; 95():682-688. PubMed ID: 27923566
[TBL] [Abstract][Full Text] [Related]
3. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
5. Flavonolignans inhibit the arachidonic acid pathway in blood platelets.
Bijak M; Saluk-Bijak J
BMC Complement Altern Med; 2017 Aug; 17(1):396. PubMed ID: 28797264
[TBL] [Abstract][Full Text] [Related]
6. Flavonolignans reduce the response of blood platelet to collagen.
Bijak M; Dziedzic A; Saluk-Bijak J
Int J Biol Macromol; 2018 Jan; 106():878-884. PubMed ID: 28842200
[TBL] [Abstract][Full Text] [Related]
7. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
8. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
[TBL] [Abstract][Full Text] [Related]
9. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
10. Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes.
Bijak M; Dziedzic A; Synowiec E; Sliwinski T; Saluk-Bijak J
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28914761
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
12. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation.
Tseng YL; Chiang ML; Lane HY; Su KP; Lai YC
Thromb Res; 2013 Apr; 131(4):325-32. PubMed ID: 23490430
[TBL] [Abstract][Full Text] [Related]
13. Curcumin by activation of adenosine A
Rukoyatkina N; Shpakova V; Bogoutdinova A; Kharazova A; Mindukshev I; Gambaryan S
Biochem Biophys Res Commun; 2022 Jan; 586():20-26. PubMed ID: 34823218
[TBL] [Abstract][Full Text] [Related]
14. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.
Bijak M; Synowiec E; Sitarek P; Sliwiński T; Saluk-Bijak J
Nutrients; 2017 Dec; 9(12):. PubMed ID: 29240674
[TBL] [Abstract][Full Text] [Related]
16. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
Kuliczkowski W; Rychlik B; Chiżyński K; Watała C; Golański J
Pol Arch Med Wewn; 2011 Apr; 121(4):115-21. PubMed ID: 21532533
[TBL] [Abstract][Full Text] [Related]
18. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
20. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
